|
Contemporary utilization trends of systemic chemotherapy for upper tract urothelial carcinoma (UTUC). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Visible Health |
Leadership - Visible Health |
Stock and Other Ownership Interests - Visible Health |
Honoraria - Genomic Health |
Consulting or Advisory Role - Genomic Health |
Speakers' Bureau - Genomic Health |
Travel, Accommodations, Expenses - Genomic Health |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Bayer (Inst); Medivation (Inst); Millennium (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Tokai Pharmaceuticals |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - GlaxoSmithKline; Johnson & Johnson |
Consulting or Advisory Role - Myriad Genetics |
Speakers' Bureau - Janssen Oncology |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |